This concurrent resolution directs the President to withdraw United States Armed Forces from any hostilities against Iran. It specifically invokes the War Powers Resolution, mandating this removal unless Congress formally declares war or provides specific authorization for military force against Iran. The bill clarifies that it does not prevent the U.S. from acting in self-defense, maintaining a defensive troop presence in the region, or continuing intelligence activities related to threats from Iran.
This bill reauthorizes and expands the Accelerating Access to Critical Therapies for ALS Act through 2031, extending funding for research into treatments for amyotrophic lateral sclerosis. It requires drug manufacturers to share interim clinical trial data with the FDA to better assess the progress of investigational drugs and clarifies that phase 3 clinical trial definitions include combined phase 2/3 trials and planned trials not yet enrolling participants. The legislation also mandates the FDA to publish an updated five-year action plan for ALS and other rare neurodegenerative diseases, including resource needs and coordination strategies with broader disease communities. Additionally, the bill requires the Government Accountability Office to submit a report on the program's implementation four years after enactment.
The Main Street Capital Access Act reduces regulatory burdens for smaller banks, particularly those with less than $10 billion in assets. Key provisions include a 3-year phase-in period for new banks to meet capital requirements, lower leverage ratio requirements for rural banks (7.5% for the first 2 years), and a 30-day review process for business plan deviations. The bill also establishes an Office of Independent Examination Review, sets specific timelines for examinations (270 days) and reports (90 days), and creates a "least cost exception" for bank resolutions to prevent excessive concentration of the banking system. These changes aim to promote new bank formation, improve regulatory efficiency, and support community banking while maintaining financial stability.
This bill, known as the Putting Patients First by Strengthening Provider Accountability in FECA Act, aims to improve oversight of healthcare providers who receive payments under the Federal Employees Health Benefits program. It directly affects medical service providers, suppliers, and the Department of Labor by introducing a new rule that allows the Secretary of Labor to suspend payments to any provider convicted of fraud in this program, federal health care benefit programs, or similar state programs. The law requires the Secretary to issue regulations to enforce this suspension authority and specifies that the changes will take effect 180 days after the bill is enacted.
This bill reauthorizes and updates the American Battlefield Protection Program through 2036, extending funding for battlefield preservation grants. It increases the maximum grant percentage for battlefield interpretation projects from 50% to 75% and sets $2 million annually for battlefield restoration grants through 2036. The bill also requires the National Park Service to study French and Indian War (1754-1763) and Mexican-American War (1846-1848) sites across the U.S., assessing their significance, threats, and preservation options. These studies must involve state governors, tribal governments, local officials, and historic preservation groups, with a final report due to Congress within two years of funding. The program directly affects federal, state, tribal, and local entities managing historic battlefields.
The NIH IMPROVE Act (HR 6238) establishes a new NIH research initiative focused on improving maternal health outcomes in the U.S. It directly affects pregnant and postpartum women, particularly those in communities experiencing health disparities linked to higher maternal mortality and severe maternal morbidity. The bill authorizes $73.4 million annually (2026-2031) for NIH to fund research targeting preventable causes of maternal deaths, reduce health disparities, and evaluate community-based interventions. Key provisions require NIH to advance evidence-based solutions through grants and studies on biological, behavioral, and regional factors affecting maternal health before, during, and after pregnancy.
This bill reauthorizes funding for the C.W. Bill Young Cell Transplantation Program, setting $31 million for fiscal year 2025 and $33 million annually for fiscal years 2027-2031. It also extends the deadline for the national cord blood inventory program from 2026 to 2031. The legislation directly affects stem cell research programs and cord blood banks by maintaining federal funding levels and prolonging the inventory program’s timeline. These provisions ensure continuity for existing research infrastructure and blood bank operations without introducing new policy changes.
This bill reauthorizes federal programs focused on preventing and responding to tick-borne diseases through 2026-2030, extending existing efforts beyond their previous expiration. It updates the National Strategy for Vector-Borne Diseases to emphasize identifying, reporting, preventing, and responding to these illnesses. The bill modifies two sections of the Public Health Service Act to continue funding for health departments working on vector-borne disease control. It directly affects public health programs and state/local health departments managing tick-borne disease prevention and response.
The AADAPT Act reauthorizes and expands Project ECHO grants to improve Alzheimer’s and dementia care through technology-enabled training. It specifically funds grants for healthcare providers in rural, frontier, or medically underserved areas to enhance early diagnosis, quality care, and provider retention for dementia patients. The bill authorizes $1 million annually (2027-2032) for these dementia-focused training programs, requiring funds to supplement - not replace - existing resources. This directly supports primary care providers licensed to serve underserved communities, using collaborative online learning to address care gaps.
HR 2821, the FDA Modernization Act 3.0, requires the FDA to update regulatory language within one year of enactment. It directs the agency to replace all references to "animal tests" with "nonclinical tests" in 22 specific sections of the Code of Federal Regulations related to drug development and approval processes. The bill also adds a definition for "nonclinical test" into relevant FDA regulations to align with prior legislative changes. This update applies directly to pharmaceutical manufacturers and FDA reviewers who follow these regulatory guidelines during drug development. The changes aim to modernize terminology without altering current testing requirements.
This bill requires Medicare to create separate payment codes for ultralightweight manual wheelchairs based on their frame material (specifically titanium or carbon fiber vs. other materials), starting in 2026. It ensures Medicare pays the standard rate for titanium/carbon fiber wheelchairs regardless of material, while allowing suppliers to charge beneficiaries the difference between Medicare's payment and their actual cost. Beneficiaries must receive a notice about potential additional costs before purchasing or renting such wheelchairs. The bill directly affects Medicare beneficiaries needing these specialized wheelchairs and the suppliers who provide them.
This bill reauthorizes and improves federal programs focused on preventing, detecting, and treating traumatic brain injuries (TBIs), extending funding through 2030. It updates CDC surveillance to better track high-risk groups (like military personnel, first responders, and those in certain occupations) and requires public sharing of aggregated TBI data. States receiving grants must maintain non-Federal funding levels for TBI programs, with limited waivers allowed. The bill also mandates a congressional report on high-risk populations and a study examining long-term TBI effects, including links to dementia and mental health conditions.
